Poseltinib

珀舍替尼

Report date: 2025/01/24 16:03:04
NME

Base Information

Drug NamePoseltinib
Drug Alias NameHM-71224LY3337641NB-02
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsCentral Nervous System LymphomaPrimary vitreoretinal lymphomaArthritis, Rheumatoid +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSlovakiaSingapore +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNOBO Medicine IncSeoul National University Hospital
Inactive CompaniesHanmi Pharmaceutical Co LtdEli Lilly And Company
Active IndicationsCentral Nervous System LymphomaPrimary vitreoretinal lymphomaLymphoma, Large B-Cell, Diffuse
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A